Related Experiment Video
Updated: Dec 1, 2025

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model
Published on: June 29, 2014
Cardiac and Vascular α1-Adrenoceptors in Congestive Heart Failure: A Systematic Review
Gizem Kaykı-Mutlu1, Olga Papazisi2, Meindert Palmen2
1Department of Pharmacology, Faculty of Pharmacy, Ankara University, 06560 Ankara, Turkey.
Insights
Heart failure involves sympathetic nervous system activation. Unlike beta-receptors, alpha-1 receptors (α1-ARs) show no consistent downregulation or desensitization in heart failure, making their therapeutic role uncertain.
Area of Science:
- Cardiovascular Physiology
- Pharmacology
Background:
- Heart failure (HF) is a global health concern requiring improved treatments.
- Sympathetic activation in HF stimulates alpha- and beta-adrenoceptors (ARs).
- Beta-ARs are well-known to downregulate and desensitize in HF, but alpha-AR roles are less understood.
Purpose of the Study:
- To systematically review the role of cardiac and vascular alpha-1 adrenoceptors (α1-ARs) in heart failure.
- To summarize changes in α1-AR expression, signaling, and responses during HF.
Main Methods:
- Systematic literature review across 5 databases.
- Focused on studies investigating cardiac and vascular α1-ARs in HF.
Main Results:
- All three α1-AR subtypes (α1A, α1B, α1D) are expressed in human and animal cardiovascular tissues.
- Evidence for α1-AR downregulation or desensitization in HF is inconsistent, unlike β-ARs.
- Conflicting findings exist regarding the impact of HF on α1-AR expression and function.
Conclusions:
- The role of α1-ARs in HF pathogenesis requires further investigation.
- Unlike β-ARs, α1-ARs do not show consistent downregulation or desensitization in HF.
- The therapeutic potential of targeting α1-ARs in HF remains debatable.
Abstract:
As heart failure (HF) is a devastating health problem worldwide, a better understanding and the development of more effective therapeutic approaches are required. HF is characterized by sympathetic system activation which stimulates α- and β-adrenoceptors (ARs). The exposure of the cardiovascular system to the increased locally released and circulating levels of catecholamines leads to a well-described downregulation and desensitization of β-ARs. However, information on the role of α-AR is limited. We have performed a systematic literature review examining the role of both cardiac and vascular α1-ARs in HF using 5 databases for our search. All three α1-AR subtypes (α1A, α1B and α1D) are expressed in human and animal hearts and blood vessels in a tissue-dependent manner. We summarize the changes observed in HF regarding the density, signaling and responses of α1-ARs. Conflicting findings arise from different studies concerning the influence that HF has on α1-AR expression and function; in contrast to β-ARs there is no consistent evidence for down-regulation or desensitization of cardiac or vascular α1-ARs. Whether α1-ARs are a therapeutic target in HF remains a matter of debate.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure II: Pathophysiology
Heart Failure Drugs: β-Blockers
Pathophysiology of Heart Failure
Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Heart Failure V: Medical Management

